Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer

Overview of attention for article published in PLOS ONE, March 2013

Altmetric Badge

Mentioned by

news: 1 news outlet
twitter: 1 X user

f1000: 1 research highlight platform

Citations

dimensions_citation: 185 Dimensions

Readers on

mendeley: 79 Mendeley

Summary News X Research highlights Dimensions citations

So far, Altmetric has seen 1 news story.

Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer

PLoS Medicine, 23 Dec 2021

Notice of republication This article was republished on October 20, 2020, to remove a Supporting Information file that was…